R. Michael Carruthers - May 1, 2023 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Financial Officer
Signature
/s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers
Stock symbol
EWTX
Transactions as of
May 1, 2023
Transactions value $
-$11,897
Form type
4
Date filed
5/3/2023, 06:26 PM
Previous filing
Aug 10, 2022
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $0 +5.21K +42.5% $0.00 17.5K May 1, 2023 Direct F1
transaction EWTX Common Stock Sale -$11.9K -1.34K -7.65% $8.90 16.1K May 2, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Restricted Stock Units Options Exercise $0 -5.21K -33.33% $0.00 10.4K May 1, 2023 Common Stock 5.21K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 254 shares purchased on November 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.